MASLD patient advocates consider the impact Rezdiffra approval and accompanying promotion and education might have on the U.S. healthcare system.
This conversation focuses on how the role of MASLD patient advocates might change and expand in the aftermath of Rezdiffra being approved. MAFLD patient advocates consider how their roles might change and expand now that Rezdiffra has been approved.
Patient advocates, led by GLI’s Jeff McIntyre, discuss advocates’ goals for a MASH drug label and the steps they took to communicate this information to FDA.
Five leading MASLD patient advocates discuss their initial reactions when Rezdiffra became the first MASH drug approved in the US on March 14.
Leading patient advocates help the Surfers identify the target MASH patients for Rezdiffra and discuss Madrigal’s extensive patient support program.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
The conversation on Rezdiffra, the first MASH drug, wraps up with the panelists answering a inviation to discuss any other issues of interest that had not arisen in the conversation.
This conversation focuses on what panelists believe to be the major lessons the BioPharma industry should take from Madrigal’s success in bring Rezdiffra to launch.
The launch of Rezdiffra raises this pivotal question: which MASH patients are the correct initial targets for the first MASH drug?
As panelists ponder practical issues about when and to whom to prescribe Rezdiffra, they consider the benefits and shortcomings of existing NITs.
